12:44 , Mar 21, 2019 |  BC Innovations  |  Emerging Company Profile

A Passage to optimal CNS vectors

Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched...
13:50 , Mar 14, 2019 |  BC Extra  |  Financial News

With new data in hand, Axovant raises $40M

Days after revealing the first clinical data from its gene therapy pipeline, Axovant raised $40 million through the sale of 26.7 million shares at $1.50 in a follow-on offering. Axovant Sciences Ltd. (NASDAQ:AXGT) proposed the...
20:28 , Mar 11, 2019 |  BC Extra  |  Clinical News

Axovant reports first clinical gene therapy data

After rebooting to focus exclusively on gene therapies, Axovant gained $0.21 (14%) to $1.69 on Monday after reporting its first data from its retooled pipeline. The lowest dose of its Parkinson's disease therapy, AXO-Lenti-PD, was...
20:10 , Mar 1, 2019 |  BC Week In Review  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
00:14 , Feb 23, 2019 |  BC Extra  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
01:17 , Feb 16, 2019 |  BC Extra  |  Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy...
18:23 , Feb 15, 2019 |  BC Week In Review  |  Company News

Axovant spins out small molecule team to form CNS-focused newco

Following its pivot to gene therapy, Axovant Sciences Ltd. (NASDAQ:AXON) has spun out its small molecule team into Arvelle Therapeutics GmbH (Basel, Switzerland). The newco has raised more than $100 million and in-licensed exclusive European...
23:28 , Feb 14, 2019 |  BC Extra  |  Company News

Axovant spins out small molecule team to form CNS-focused newco

Following its pivot to gene therapy, Axovant Sciences Ltd. (NASDAQ:AXON) has spun out its small molecule team into Arvelle Therapeutics GmbH (Basel, Switzerland). The newco has raised more than $100 million and in-licensed exclusive European...
19:29 , Dec 21, 2018 |  BC Week In Review  |  Company News

Axovant gets rights to gene therapies from UMass medical school

The University of Massachusetts Medical School (Worcester, Mass.) granted Axovant exclusive, worldwide rights to develop and commercialize two gene therapies to treat GM1 and GM2 gangliosidoses. The school received $10 million up front and is...
18:36 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Axovant discontinues development of nelotanserin after Phase II readout

Axovant Sciences Ltd. (NASDAQ:AXON) discontinued development of nelotanserin after the product missed the primary endpoint in a Phase II trial to treat REM sleep behavior disorder in patients with Lewy body dementia. The double-blind trial...